Abstract

The present invention provides a pharmaceutical composition comprising a monoclonal antibody which binds to human IGF2BP1 present on the cell surface of a target cell and optionally a pharmaceutically acceptable carrier, diluent or excipient, wherein said target cell is a non-permeabilized cell or a living cell. The present invention further provides said pharmaceutical composition for use in an in-vivo imaging method or in a method for the treatment of cancer in a human subject. Further is provided a method for determining whether a human subject may suffer from cancer, comprising determining whether IGF2BP1 is present on the cell surface of cancer cells and/or determining whether IGF2BP1 is present on the surface of extracellular vesicles. Additionally, an antibody which binds to human IGF2BP1 present on the cell surface of a target cell and/or which binds to human IGF2BP1 present on the surface of an extracellular vesicle is provided. The present invention also provides a method of killing a target cell having IGF2BP1 present on the cell surface using an antibody. Furthermore, an antibody is provided, which binds to human IGF2BP1 present on the cell surface of a target cell for use in a method for the treatment of cancer in a subject, comprising, prior to the treatment of cancer in said subject, determining whether a target cell of said subject has IGF2BP1 present on the cell surface.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to a nanoparticle (1) having core (2), a first surface functionalization (4), and a second surface functionalization (5). The core (2) comprises or consists of a metal, preferably silver. An inorganic coating (3) is arranged around the core (2). The coating (3) preferably comprises or consists of gold. The first surface functionalization (4) is adapted to provide colloidal stability of the nanoparticle (1) in, preferably aqueous, solvents (19). The first functionalization (4) substantially prevents non-specific binding of macromolecules (55), in particular macromolecules including proteins, DNA, and/or RNA. The second surface functionalization (5) includes one of a binding site for a binding partner, preferably a binding site for a poly-histidine tag of a biomolecule (55), and a biomolecule, preferably a protein.

IPC Classes  ?

• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/553 - Metal or metal coated
• G01N 33/557 - ImmunoassayBiospecific binding assayMaterials therefor using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction

Abstract

The present invention relates to a composition comprising a bacteriophage comprising a nucleic acid molecule having a nucleotide sequence encoding a polypeptide having butyryl- coenzyme A (CoA):acetate CoA-transferase (BCoAT) activity, wherein said bacteriophage is capable of being propagated in (Pseudo)Flavonifractor sp., Lawsonibacter sp., Mycobacterium sp., Megashaera sp. or Alistipes sp. cells. The present invention also relates to nutritional compositions and medical compositions comprising such bacteriophages. The present invention further relates to such compositions for use in methods of treating an inflammatory or immune-mediated intestinal condition of a subject. The present invention further relates to methods for detecting a bacteriophage comprising a nucleic acid molecule having a nucleotide sequence encoding a polypeptide having butyryl-coenzyme A (CoA):acetate CoA-transferase (BCoAT) activity. Furthermore, the present invention relates to a kit comprising such compositions.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 37/02 - Immunomodulators
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 9/10 - Transferases (2.)
• C12P 7/52 - Propionic acidButyric acids

Abstract

The invention provides a method of preparing a biocompatible hydrogel, a hydrogel obtainable by that method, a biocompatible hydrogel for non-covalent immobilization of one or more enzyme(s), and a composition including any of those hydrogels. The invention further provides a method for encapsulating one or more enzyme(s) in a hydrogel as described herein and the use of any of said hydrogels for non-covalent immobilization of one or more enzyme(s) in the hydrogel or the use of any of said hydrogels in a biosensor. Additionally, the present invention provides a kit containing the composition or the hydrogel according to the present invention.

IPC Classes  ?

• C12N 11/10 - Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a carbohydrate
• C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
• C08B 37/02 - DextranDerivatives thereof
• C12N 9/04 - Oxidoreductases (1.), e.g. luciferase acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)

Abstract

The disclosure relates to an apparatus for optoacoustic sensing of tissue features, such as tissue architecture, morphological information, functional, physiological and/or molecular information regarding biomolecules, in particular metabolites, in biological tissue (1) and to according methods. The apparatus comprises: at least one irradiation device (2) configured to irradiate the tissue (1) with a first electromagnetic radiation (3) exhibiting one or more wavelengths or wavelength ranges in a first spectral range; at least one detection device (5) configured to detect at least one first optoacoustic signal corresponding to ultrasound waves (6) emanating from a region of interest (ROI) in the tissue (1) in response to irradiating the tissue (1) with the first electromagnetic radiation (3); and a processor (7) configured to determine, based on the first optoacoustic signal, at least one first parameter characterizing a first tissue feature of interest in the region of interest (ROI).

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters

Abstract

The present invention relates to a method for diagnosing mycosis fungoides (MF) or eczema and/or distinguishing MF from eczema or psoriasis, the method comprising: determining an expression of at least one biomarker in a sample, differentiating between MF and eczema and/or ecema or psoriasis, based on the expression of the at least one biomarker in the sample, and generating a differential diagnosis finding based on the expression of the at least one biomarker in the sample The present invention also relates to a system a system for diagnosing mycosis fungoides (MF) or eczema and/or distinguishing MF from eczema or psoriasis, the system comprising: a processing component configured to output at least one dataset, and an analyzing component configured to analyze the at least one dataset, wherein the analyzing component comprises: a determining module configured to determine an expression of at least one biomarker in a sample, a differentiating module configured to differentiate between MF and eczema and/or eczema or psoriasis, based on the expression of the at least one biomarker in the sample, and a finding generating module configured to generate a differential diagnosis finding based on the expression of the at least one biomarker in the sample. Furthermore, the invention relates to a kit for use in a method for diagnosing eczema or mycosis fungoides, and/or distinguishing MF from eczema or psoriasis, the kit comprising at least one mean for quantifying an expression of at least one biomarker in at least one sample.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The present invention relates to novel anti-FLT3 antibodies for specifically targeting extracellular domain of FLT3. The present invention further relates to targeting FLT3 by novel antibody-drug-conjugates (ADCs) based on the novel anti-FLT3 antibodies of the present invention, especially in combination with kinase inhibitors, for use in therapy and/or for use in a method of cancer treatment (e.g., acute myeloid leukemia (AML) with or without internal tandem duplication (ITD) mutations in the FLT3 gene (FLT3-ITD)).

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

A tyrosine kinase receptor inhibitor or a pharmaceutically acceptable salt, a solvate, a metabolite, or a derivative thereof for use in a method of treatment of a disease associated with tyrosine kinase receptor activation in a subject, wherein the tyrosine kinase receptor inhibitor is administered in combination with a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof; wherein: R1188)alkyl; and R2188)alkyl; and/or a compound of formula (II): wherein: R3, R4and R518188)alkylene; Y is halogen; and AΘ is a pharmaceutically acceptable anion.

IPC Classes  ?

• A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
• A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol

Abstract

The present invention relates to novel TRAF2 inhibitors for use in the treatment of cancer and use of novel TRAF2 inhibitors in biochemical assays, cell culture systems, or animal models.

IPC Classes  ?

• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• A61P 35/00 - Antineoplastic agents
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings

Abstract

The present invention relates to a method of expansion of pancreas progenitors under GMP-compliant conditions. The present invention relates to a method of expansion of pancreas progenitors under GMP-compliant conditions, cells produced by said method (e.g., expanded PP (ePP) cells) as well as uses of said cells in various applications (e.g., clinical applications).

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

The present invention refers to novel UV-light cleavable drug conjugates comprising a diazirine linker.

IPC Classes  ?

• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• C07D 203/04 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings

Abstract

The disclosure relates to a computer-implemented method and an apparatus for pro- cessing optical coherence tomography (OCT) images of vascular tissue, in particular neointima, and a system for OCT imaging of vascular tissue. The method comprises training a first artificial neural network (1) comprising the following steps: a) providing or receiving a plurality of first cross-sectional OCT training images (11) of one or more blood vessels, b) determining, for each first OCT training image (11 ), a center point (C) of a first image segment (2T) representing a lumen of the blood vessel in the respective first OCT training image (11), c) dividing each first OCT training image (11) into OCT training image sections (QT-Q4'), in particular quadrants, located around the center point (C) of the respective first OCT training image (11), thereby obtaining a plurality of OCT training image sections (QT-Q4'), d) assigning a classification information (A1- A4) to each OCT training image section (QT-Q4'), the classification information (A1- A4) classifying the respective OCT training image section (QT-Q4') with respect to vascular tissue, in particular with respect to neointima, of the blood vessel represented in the respective OCT training image section (QT-Q4'), and e) training the first artificial neural network (1), which comprises an input layer (1a) and an output layer (1 b), the training comprising: i) inputting the plurality of OCT training image sections (QT-Q4') at the input layer (1a), ii) obtaining, for each inputted OCT training image section (QT- 04'), an output classification information (01-04) at the output layer (1b), the output classification information (01-04) classifying the respectively inputted OCT training im- age section (QT-Q4') with respect to vascular tissue, in particular with respect to neo- intima, of the blood vessel represented in the respectively inputted OCT training image section (QT-Q4'), and iii) comparing, for each inputted OCT training image sec- tion (QT-Q4'), the output classification information (01-04) with the classification in- formation (A1-A4) assigned to the respectively inputted OCT training image sec- tion (QT-Q4'), in particular by computing a loss function X which quantifies a difference between the classification information (A1-A4) assigned to the respectively inputted OCT training image section (QT-Q4') and the output classification information (01 to 04).

IPC Classes  ?

• G06T 7/00 - Image analysis
• G06T 7/11 - Region-based segmentation
• G06T 7/66 - Analysis of geometric attributes of image moments or centre of gravity

Abstract

The present invention relates to an in vitro method of generating cells capable of differentiating to a multicellular organoid unit that morphologically and/or functionally recapitulates invasive and/or ductal cell growth. The present invention further relates to a method of screening for an anti-migratory drug using a multicellular organoid unit obtained in the in vitro method. Additionally, the present invention relates to a culture medium and the respective use of said culture medium in any of said methods according to the present invention.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/09 - Tumour cells

Abstract

The present invention relates to a novel dimer composed of a first Fab monomer and a second Fab monomer, each Fab monomer comprising a VH and a VL region, wherein two of such VH or VL regions are covalently linked by a disulfide bond between an additional non-naturally occurring cysteine residue at their respective N-termini.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The present invention relates to an ex vivo analytic method for analysis of a sample (S1), comprising the steps: A) Determining Fe2+, Fe3+, Fe-Ferritin and total Fe content in sample (S1), comprising the steps: A1) Separating simultaneously Fe2+, Fe3+ and Fe-Ferritin present in a sample (S1); and A2) Quantifying simultaneously Fe2+, Fe3+, Fe-Ferritin separated in step A1) and total Fe based on sample (S1); B) Determining S and Se containing compounds content of sample (S1), comprising the steps B1) Separating simultaneously S and Se containing compounds present in sample (S1); and B2) Quantifying simultaneously S and Se containing compounds separated in step B1) of sample (S1). Further, the invention relates to a kit for performing the analytic method.

IPC Classes  ?

• G01N 33/90 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving iron binding capacity of blood
• G01N 27/447 - Systems using electrophoresis
• H01J 49/10 - Ion sourcesIon guns

Abstract

The invention is directed to a quinone for use in the inhibition of ferroptosis.

IPC Classes  ?

• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The invention provides a method of preparing a biocompatible hydrogel, a hydrogel obtainable by said method and a biocompatible hydrogel. The present invention further provides a cofactor comprising at least one group(s) Z comprising or being a functional group suitable for a 1,3- dipolar cycloaddition. Additionally, the present invention provides a composition comprising any of said hydrogels according to the invention. The invention further provides the use of any of said hydrogels for non-covalent immobilization of at least one enzyme(s) in the hydrogel, or as a catalyst, or in a biosensor. Additionally, the present invention provides a kit comprising the hydrogel according to the present invention.

IPC Classes  ?

• C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
• C08B 37/02 - DextranDerivatives thereof
• C08B 37/08 - ChitinChondroitin sulfateHyaluronic acidDerivatives thereof
• C08J 3/075 - Macromolecular gels
• C08L 5/00 - Compositions of polysaccharides or of their derivatives not provided for in group or
• C08L 5/02 - DextranDerivatives thereof
• C08L 5/04 - Alginic acidDerivatives thereof
• C08L 5/08 - ChitinChondroitin sulfateHyaluronic acidDerivatives thereof

Abstract

The present invention provides novel IGFR-L1 antibodies for targeting extracellular domain of non-denatured IGFR-L1 protein. Said antibodies are envisaged for use as a medicament, and in particular for treatment of diabetes and related disorders and cancer.

IPC Classes  ?

• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention provides a novel IGFR-like receptor 2 and antagonists and agonists for targeting said receptor. Said antagonists and agonists are envisaged for use as a medicament, and in particular for treatment of cancer or diabetes.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to a composition comprising proteins identified in barn dust extract or peptides derived from one of the proteins. The composition is useful in the prevention or treatment of a disease.

IPC Classes  ?

• A61K 39/36 - Allergens from pollen
• A61K 39/35 - Allergens
• A61P 11/06 - Antiasthmatics
• A61P 37/08 - Antiallergic agents

Abstract

The disclosure provides methods and compositions for treating HBV. Disclosed is an HBcAg particle, comprising HBV core proteins from at least two different HBV genotypes, and a vaccine vector comprising a nucleotide sequence having ≥90% sequence identity to SEQ ID NO: 5. Disclosed are respective pharmaceutical compositions and their uses in therapy, for medicament manufacture and a vaccination method. Said vaccination method comprises administering to a human (i) a first dose and (ii) a second dose of an HBcAg particle and of an HBsAg, and (iii) a dose of a vaccine vector that expresses a HBsAg from HBV genotype A, a HBcAg from HBV genotype D, a HBsAg having ≥90% sequence identity to SEQ ID NO: 7, a HBcAg having ≥90% sequence identity to SEQ ID NO: 8 or 17, and an RT domain having ≥90% sequence identity to SEQ ID NO: 9.

IPC Classes  ?

• A61K 39/29 - Hepatitis virus
• A61P 31/20 - Antivirals for DNA viruses

Abstract

The present invention relates to new cinnamic add amides which may be used for treatment of fibrosis and neoplasia and to cinnamic acid amides for use in the treatment of fibrosis, neoplasia, arthrolithiasis, familiar mediterranean fever and pericarditis. Further, the invention relates to a pharmaceutical composition comprising said cinnamic acid amides and to a screening essay for identifying compounds suitable for the treatment of fibrosis.

IPC Classes  ?

• C07C 235/38 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/245 - Amino benzoic acid types, e.g. procaine, novocaine
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
• A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
• A61K 31/37 - Coumarins, e.g. psoralen
• A61K 31/396 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/415 - 1,2-Diazoles
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/4192 - 1,2,3-Triazoles
• A61K 31/42 - Oxazoles
• A61K 31/4245 - Oxadiazoles
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/4402 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
• C07C 317/32 - SulfonesSulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
• C07C 325/02 - ThioketonesOxides thereof
• C07D 209/08 - IndolesHydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
• C07D 213/643 - 2-PhenoxypyridinesDerivatives thereof
• C07D 213/75 - Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
• C07D 229/02 - Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms containing three-membered rings
• C07D 231/20 - One oxygen atom attached in position 3 or 5
• C07D 235/08 - Radicals containing only hydrogen and carbon atoms
• C07D 249/04 - 1,2,3-TriazolesHydrogenated 1,2,3-triazoles
• C07D 271/12 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
• C07D 307/81 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
• C07D 307/87 - Benzo [c] furansHydrogenated benzo [c] furans
• C07D 311/20 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
• C07D 311/58 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4
• C07D 317/60 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 319/18 - Ethylenedioxybenzenes, not substituted on the hetero ring
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

The present invention relates to a DNA-probe comprising a) a DNA-binder (DNAB); b) a tracer (T) c) optionally a linker (L) connecting the DNA-binder (DNAB) and the tracer (T).

IPC Classes  ?

• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

New PCT-application based on EP 23 154 047.7 Ludwig-Maximilians-Universität München, Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt Vossius Ref.: AF3867 PCT S3 ABSTRACT The present invention relates to the recognition of CD86 as a marker of hematological cancer and thus relates to CD86 targeting agents for the treatment of such cancers, in particular, acute myeloid leukemia (AML), Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). The invention in particular encompasses a lymphocyte recombinantly expressing a chimeric antigen T cell receptor (CAR) comprising an antigen binding domain that specifically binds CD86 for use in the treatment of such cancers, as well as also encompassing the CAR construct, i.e., comprising an antigen binding domain that specifically binds CD86.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/725 - T-cell receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention relates to fusion proteins comprising (a) an extracellular domain containing a polypeptide derived from PD-1 or CD40L at its N-terminus; (b) a transmembrane domain; and (c) an intracellular domain containing a polypeptide derived from 4-1 BB or CD28 at its C-terminus.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C12N 15/62 - DNA sequences coding for fusion proteins

Abstract

The invention relates to a device and a method for determining one or more parameters regarding a content and/or property of biomolecules, in particular metabolites, in a biological tissue (11). The device comprises at least one irradiation unit (1) configured to irradiate the tissue (11) with electromagnetic radiation (2) exhibiting one or more wavelengths or wavelength ranges, in particular in the mid-infrared, near-infrared and/or visible spectral range, at least one detection unit (8, 12) configured to detect, in a spatially resolved manner, first signals corresponding to optical and/or optoacoustic and/or optothermal signals emanating from the tissue (11) in response to irradiating the tissue (11) with electromagnetic radiation (2), in particular in the near-infrared and/or visible spectral range, wherein the at least one irradiation unit (1) and the at least one detection unit (8, 12) are located in the same half space above and/or adjacent to the irradiated tissue (11), and a processing unit (14) configured i) to localize, based on the detected first signals, a location or region of interest on and/or within the tissue (11), at which at least one biomolecule of interest is present or expected, ii) to control the at least one irradiation unit (1) to irradiate the location or region of interest on and/or within the tissue (11) with electromagnetic radiation (2) exhibiting a time-varying intensity and one or more wavelengths or wavelength ranges in the mid-infrared spectral range, iii) to control the at least one detection unit (8, 12) to detect second signals corresponding to optoacoustic and/or optothermal signals emanating from the irradiated location or region of interest on and/or within the tissue (11) in response to irradiating the location or region of interest on and/or within the tissue (11) with the electromagnetic radiation (2) in the mid-infrared spectral range, and iv) to determine, based on the detected second signals, one or more parameters regarding a content and/or property of the at least one biomolecule, in particular metabolite, of interest at the location or region of interest on and/or within in the tissue (11).

IPC Classes  ?

• G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated

Abstract

The present invention relates to a cell of the human immune system transduced or transfected with a T cell receptor (TCR) or chimeric antigen receptor (CAR), said cell being further modified to render its MALT1 protease activity constitutive active. The present invention further relates a said cell of the human immune system for use as a medicament. In particular, the present invention relates to said cell for use in adoptive T cell therapy. The invention also comprises a cell of the human immune system transduced or transfected with a T cell receptor (TCR) or chimeric antigen receptor (CAR), and further modified to render its MALT1 protease activity constitutive active for use in a method of treating cancer. The invention also relates to a method for generating a cell of the human immune system, comprising modifying a cell to render MALT1 protease activity constitutive active. The invention further relates to an in vitro method of enhancing the activity of a cell of the human immune system transduced or transfected with a T cell receptor (TCR) or chimeric antigen receptor (CAR), comprising modifying said cell in that MALT1 is rendered constitutive active. The invention also comprises an in vitro use of constitutive active MALT1 for enhancing the activity of a cell transduced or transfected with a T cell receptor (TCR) or chimeric antigen receptor (CAR).

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin

Abstract

The invention relates to a computer-implemented method for obtaining a pharmaceutically active substance. The pharmaceutically active substance functions as a ligand in a target-ligand complex. The method comprises selecting a target substance comprising a target molecular structure. The method comprises defining the target molecular structure within a multidimensional tensor. The method comprises translating the tensorized target molecular structure into a voxelated three-dimensional target preference map by a machine-learning algorithm. The machine-learning algorithm is trained with training data comprising chemical structures of target-ligand complexes. Each voxel of the target preference map is assigned preference scores by the machine-learning algorithm. Each preference score comprises a value of a relative preference towards a specific atom property. The method further comprises predicting one or more ligand properties for a pharmaceutically active substance by evaluating a target-ligand interaction based on the preference score.

IPC Classes  ?

• G16C 20/50 - Molecular design, e.g. of drugs

Abstract

The invention relates to a method, an apparatus and system for characterizing transient interactions between biomoleules. wherein the method comprises following steps: providing a plurality of plasmonic nanoparticles which are configured to allow first biomolecules to adhere thereto: providing a mixture comprising the nanoparticles. first biomolecules and second biomolecules to allow the first biomolecules to adhere to the nanoparticles and to allow the second biomolecules to. in particular transiently, interact with the first biomolecules adherent to the nanoparticles: irradiating the mixture with first electromagnetic radiation, in particular broadband electromagnetic radiation: detecting second electromagnetic radiation, which is scattered by the mixture while irradiating the mixture with the first electromagnetic radiation, in a time-resolved and spectrally-resolved manner so as to obtain intensity signals representing changes in the spectrum of the detected second electromagnetic radiation: and determining at least one interaction parameter characterizing transient interactions of the second biomolecules with the first biomolecules based on the intensity signals.

IPC Classes  ?

• G01N 21/47 - Scattering, i.e. diffuse reflection

Abstract

AcinetobacterbaumanniiAcinetobacter baumanniiAcinetobacter baumannii. Additionally, the present invention relates to kits and to a method of preparing said composition comprising isolated phages and a composition comprising isolated phages obtainable or obtained by said method.

IPC Classes  ?

• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61P 31/04 - Antibacterial agents
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient

Abstract

The present invention relates to novel 3-Phenylquinazolinones in particular for the use in the treatment of cancer.

IPC Classes  ?

• C07D 239/72 - QuinazolinesHydrogenated quinazolines
• C07D 239/91 - Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
• C07D 471/04 - Ortho-condensed systems
• C07D 495/04 - Ortho-condensed systems
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a methanobactin reducing Fe3+ ions to Fe2+ ions for use in medicine and a pharmaceutical composition comprising said methanobactin as well as to a process for reducing Fe3+ ions to Fe2+ ions ex vivo.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof

Abstract

The present invention relates to CRISPR-mediated means and methods, e.g., for adjustably induction of multiple gene expression and subsequent cell reprogramming. Particularly, the CRISPR-mediated means and methods of the present invention relate to conversion of endogenous glial cells into GABAergic neurons representing an effective method for cell reprogramming.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61P 25/16 - Anti-Parkinson drugs
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

Described herein is a genetically modified plant or non-human animal having reduced expression of an endogenous target gene.

IPC Classes  ?

• A01K 67/0278 - Knock-in vertebrates, e.g. humanised vertebrates
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

ex vivoex vivo with one or more oligonucleotide agents capable of controlling and/or reducing the differentiation of the T cell, for example through PD-1 silencing induced by chemically modified double stranded nucleic acid molecules. In some embodiments, compositions and methods described by the disclosure are useful as immunogenic modulators for treating cancer, such as melanoma.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Goods & Services

Conducting employee incentive award programs; Conducting employee incentive award programs in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Administration of loyalty and incentive schemes; Administration of loyalty and incentive schemes in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Organisation, operation and supervision of an incentive scheme; Organisation, operation and supervision of an incentive scheme in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders. Provision of prepaid cards and tokens; Provision of tokens of value in relation to incentive, bonus and reward schemes for drinking bottles, pens, notepads, running shirts and children's books; Provision of prepaid cards and tokens of value in relation to incentive, bonus and reward schemes, only in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Issuing of tokens of value in relation to incentive schemes; Issuing of tokens of value in relation to incentive, bonus and reward schemes, for drinking bottles, pens, notepads, running shirts or children's books; Issuing of tokens of value in relation to incentive schemes in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders. Information (Education -); Information (Education -) in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Publishing, reporting, and writing of texts; Publishing, reporting, and writing of texts in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Publishing of medical publications; Publishing of medical publications in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Publication of medical texts; Publication of medical texts in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Publishing of scientific papers in relation to medical technology; Publishing of scientific papers in relation to medical technology in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Publishing and issuing scientific papers in relation to medical technology; Publishing and issuing scientific papers in relation to medical technology in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Education, entertainment and sport services; Education, entertainment and sport services in relation to diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Education and instruction services; Education and instruction services in relation to diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Specialisation courses for doctors; Specialisation courses for doctors in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Personnel training; Personnel training in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Educational services provided by medical assistants; Educational services provided by medical assistants in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Conferences (Arranging and conducting of -); Arranging, conducting and organizing of conferences; Arranging, conducting and organizing of conferences in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Arranging and conducting of educational conferences; Arranging of educational conferences in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Publishing of newsletters; Publishing of newsletters in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Organisation of Webinars; Organisation of Webinars in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Publication of posters; Publication of posters in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Presentation of movies; Presentation of movies in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Development of educational materials; Development of educational materials in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Publication of educational materials; Publication of educational materials in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Dissemination of educational materials; Dissemination of educational materials in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders. Science and technology services; Science and technology services in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Issuing of scientific information; Issuing of scientific information in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Provision of scientific information; Provision of scientific information in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Natural science services; Natural science services in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Providing science technology information; Providing science technology information in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Compilation of scientific information; Compilation of scientific information in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; IT services; IT services for data protection; Hosting of databases; Hosting of databases in relation to diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Medical and pharmacological research services; Medical and pharmacological research services in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Information technology services for the pharmaceutical and healthcare industries; Information technology services for the pharmaceutical and healthcare industries in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Providing information on clinical studies via an interactive website; Providing information on clinical studies via an interactive website in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Providing information about the results of clinical trials for pharmaceutical products; Providing information about the results of clinical trials for pharmaceutical products in relation to diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Providing scientific information in the field of medical disorders, their treatment, prevention and screening; Providing scientific information in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders, their treatment, prevention and screening; Provision of information and data relating to medical and veterinary research and development; Provision of information and data relating to medical and veterinary research and development in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Genetic research; Genetic research in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Genetic mapping for scientific purposes; Genetic mapping for scientific purposes in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Scientific research in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Research and development services in the field of immunology; Research and development services in the field of immunology in relation to diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Hosting web portals; Hosting web portals in relation to diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Hosting of portals on the internet; Hosting of portals on the internet in relation to diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Research and development services in the field of antibody technology; Research and development services in the field of antibody technology in relation to diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Research and development services in the field of antibodies; Research and development services in the field of antibodies in relation to diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Laboratory services relating to the production of monoclonal antibodies. Human healthcare services; Human healthcare services in relation to diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Health screening; Health screening in relation to diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Diabetes screening services; Type 1 diabetes screening services; Viral and infectious diseases screening services; Severe acute respiratory syndrome coronavirus type 2 screening services; Autoimmune diseases screening services; Celiac disease screening services; Allergies screening services; Medical services; Medical services in relation to diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Providing information via the Internet in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Providing medical information; Providing medical information in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Providing health information; Providing health information in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Providing on-line information relating to the prevention, treatment and screening of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, autoimmune diseases and metabolic disorders; Diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, autoimmune diseases and metabolic disorders screening services; Genetic counseling in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, autoimmune diseases and metabolic disorders; Genetic testing for medical purposes; Genetic testing for medical purposes in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, autoimmune diseases and metabolic disorders; Genetic testing for diagnostic or treatment purposes; Genetic testing for diagnostic or treatment purposes in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, autoimmune diseases and metabolic disorders; Medical and health services relating to DNA, genetics and genetic testing; Medical and health services relating to DNA, genetics and genetic testing in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, autoimmune diseases and metabolic disorders; Medical services in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Immunodetection services for medical purposes; Immunodetection services for medical purposes in the field of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Advice relating to immunology; Advice relating to immunology in relation to diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Performing diagnosis of diseases; Performing diagnosis of diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, autoimmune diseases and metabolic disorders; Medical screening services relating to diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders; Conducting screenings for diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, autoimmune diseases and metabolic disorders risk factors; Genetic counseling; Genetic counseling in relation to diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, autoimmune diseases and metabolic disorders; Medical testing; Medical testing in relation to diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, autoimmune diseases and metabolic disorders; Medical testing for diagnostic or treatment purposes; Medical testing for diagnostic or treatment purposes in relation to diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, autoimmune diseases and metabolic disorders; Collection and preservation of human blood; Collection and preservation of human blood in relation to diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, autoimmune diseases and metabolic disorders; Medical services relating to the removal, treatment and processing of umbilical cord blood; Medical services relating to the removal, treatment and processing of umbilical cord blood in relation to diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, autoimmune diseases and metabolic disorders; Medical services relating to the removal, treatment and processing of human blood; Medical services relating to the removal, treatment and processing of human blood in relation to diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, autoimmune diseases and metabolic disorders; Medical laboratory services for the analysis of blood samples taken from patients; Medical laboratory services for the analysis of blood samples taken from patients in relation to diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, autoimmune diseases and metabolic disorders; Blood banks; Blood bank services; Cord blood bank services; Hospital services; Clinics; Clinics (Medical -); Medical treatment and diagnostics services provided by clinics and hospitals; Medical assistance consultancy provided by doctors and other specialized medical personnel; Provision of information on diabetes, autoimmune diabetes, type 1 diabetes, viral and infectious diseases, severe acute respiratory syndrome coronavirus type 2, SARS-CoV-2, celiac disease, allergies, genetics, autoimmune diseases and metabolic disorders via an online portal.

Abstract

The present invention provides a pharmaceutical composition comprising an antibody which binds to human PRDX4 present on the cell surface of a target cell and optionally a pharmaceutically acceptable carrier, diluent or excipient. The present invention further provides said pharmaceutical composition for use in a method for the treatment of cancer in a human subject. Further is provided a method for determining whether a human subject may suffer from cancer, comprising determining in a sample obtained from said human subject whether PRDX4 is present on the cell surface of cells comprised by said sample. Additionally, an antibody which binds to human PRDX4 present on the cell surface of a target cell is provided.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to composition comprising a clustered, regularly interspaced, short palindromic repeats (CRISPR) system comprising i) at least one CRISPR-associated protein 13 (Cas13) or a nucleotide sequence encoding said Cas13 protein fused with at least one nuclear localization signal (NLS) fused to at least one nuclear export sequence (NES) and ii) at least one guide RNA (gRNA) or a nucleotide sequence encoding said gRNA capable of hybridizing with one or more target RNA molecules. Further, the invention relates to a composition comprising a clustered, regularly interspaced, short palindromic repeats (CRISPR) system comprising i) at least one CRISPR-associated protein 13 (Cas13) or a nucleotide sequence encoding said Cas13 protein fused with at least one nuclear localization signal (NLS) or with at least one nuclear export sequence (NES) and ii) at least one guide RNA (gRNA) or a nucleotide sequence encoding said gRNA capable of hybridizing with one or more target RNA molecules, which is fused to at least one viral export element. The present invention also relates to said compositions for use in therapy. In particular, the present invention relates to said compositions for use in a method of preventing or treating a viral or a bacterial disease in a subject. The present invention further relates to nucleic acid molecules comprising a nucleotide sequence encoding said Cas13 protein and/or said gRNA of said compositions, vectors comprising said nucleic acid molecules and host cells comprising the vectors or the nucleic acid molecules. Further, the present invention relates to kits comprising the compositions. The invention also comprises methods of producing said compositions of the present invention.

IPC Classes  ?

• A61K 38/46 - Hydrolases (3)
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 9/22 - Ribonucleases
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61P 31/14 - Antivirals for RNA viruses

Abstract

In various embodiments a biocompatible composite membrane for in vitro cell culturing comprising a first material, which is non-water soluble and a water soluble second material is provided, wherein the composite membrane comprises a porous scaffold and a filling layer, the scaffold comprising the first material and the filling layer comprising the second material. Further, a method for fabricating the membrane, a bioreactor for use of the membrane in cell-stretch experiments and a corresponding method for investigating cells attached to the biocompatible composite membrane are also provided.

IPC Classes  ?

• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• C12M 1/00 - Apparatus for enzymology or microbiology

Abstract

The present invention relates to a novel CRISPR system comprising i) at least one nucleotide sequence encoding at least one Cast 3 protein; and ii) at least one gRNA or at least one nucleotide sequence encoding said at least one gRNA capable of hybridizing with one or more viral target RNA molecules, wherein said system comprises a viral 5' UTR or a nucleotide sequence encoding said 5' UTR and/or a viral 3* UTR or a nucleotide sequence encoding said viral 3' UTR, wherein a viral replicase recognition sequence is comprised in at least any one of said 5' UTR or in the nucleotide sequence encoding said 5' UTR, or said 3* UTR or in the nucleotide sequence encoding said 3' UTR, and wherein said system does not comprise a nucleotide sequence encoding a viral replicase and wherein said viral replicase recognition sequence is from the same RNA virus as the one or more viral target RNA molecules. The present invention also relates to a delivery system comprising the novel system and a composition comprising the novel system or the delivery system. The present invention further relates to the medical use of the novel system or in particular to the system for use in a method of preventing or treating a viral disease in a subject. Additionally, the present invention also relates to a kit comprising the novel system and to a method of producing the novel system.

IPC Classes  ?

• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/79 - Vectors or expression systems specially adapted for eukaryotic hosts

Abstract

An apparatus for photo-acoustic measurement of a measurement target in a fluid flow comprises:—an ellipsoidal measurement chamber (3) having a first focal point and a second focal point; —a duct (6, 7, 8) configured to guide a fluid flow through the measurement chamber (3) along a first axis (X) through the first focal point; —light source means for generating an excitation light beam of modulated intensity; —means configured to pass the excitation light beam through the measurement chamber (3) along a second axis (Y), which is different from the first axis (X), such that the excitation light beam crosses the fluid flow at the first focal point and that the crossing of the fluid flow and the excitation light beam defines an excitation volume (4) within which the fluid flow is excited by the excitation light beam to generate acoustic waves; and —detecting means (5) arranged at the second focal point and configured to detect said acoustic waves, wherein the detecting means has no direct contact with the fluid flow, and wherein the ellipsoidal measurement chamber has inner walls that are configured to focus the acoustic waves generated by the excitation light beam within the excitation volume (4) onto the detecting means (5).

IPC Classes  ?

• G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated
• G01N 21/31 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry

Abstract

The invention relates to a computer-implemented method and corresponding system for optoacoustic and ultrasonic imaging, a method for reconstructing optoacoustic and ultrasonic images and a method for training an artificial neural network provided therefor, the training method comprising: a) providing a model of the imaging apparatus, the model characterizing a relation between i) a spatial distribution of acoustic sources emitting and/or reflecting acoustic waves and ii) signals generated by detection elements of the imaging apparatus upon detecting the acoustic waves, b) providing several training signal sets, each training signal set comprising a plurality of training signals which were i) generated by the imaging apparatus upon imaging objects and/or ii) obtained by simulating an imaging of objects by the imaging apparatus based on the model of the imaging apparatus, c) reconstructing, based on the model of the imaging apparatus, several training image data sets from the training signal sets, each training image data set comprising image data relating to an optoacoustic and/or ultrasonic image of an object, and d) training the artificial neural network, which comprises an input layer and an output layer, the training comprising i) inputting the training signal sets at the input layer, ii) obtaining, for each inputted training signal set, an output image data set which is outputted at the output layer, and iii) comparing each output image data set with the training image data set which was reconstructed from the respectively inputted training signal set.

IPC Classes  ?

• A61B 8/08 - Clinical applications
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G06N 3/08 - Learning methods

Abstract

The invention provides a method for manufacturing a HEK293 cell line, which is capable of producing Epstein-Barr virus-like particles (EB-VLPs), as well as the HEK293 cell line obtainable by said method. The invention is further directed to a method for manufacturing EB-VLPs and a composition comprising EB-VLPs obtainable by said method for manufacturing EB-VLPs. Additionally, the invention provides a kit comprising EB-VLPs generated according to the method for manufacturing EB-VLPs. Further, the invention relates to a method for manufacturing a vaccine as well as the vaccine containing EB-VLPs obtainable by said method for manufacturing EB-VLPs.

IPC Classes  ?

• A61K 39/245 - Herpetoviridae, e.g. herpes simplex virus
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The present invention relates to near-infrared fluorescent heptamethine dyes of formula (I) and conjugates of such heptamethine dyes with favourable biodistribution and bleaching properties. The invention is further directed to the use of these compounds in diagnosis or in intraoperative surgery, in particular for use as contrast agents.

IPC Classes  ?

• C09B 23/01 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain
• C09B 23/10 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an even number of CH groups
• C09B 23/08 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an odd number of CH groups more than three CH groups, e.g. polycarbocyanines
• A61K 49/00 - Preparations for testing in vivo
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Goods & Services

Information (Education -); Information (Education -) in the field of diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Publishing, reporting, and writing of texts; Publishing, reporting, and writing of texts in the field of diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Publishing of medical publications; Publishing of medical publications in the field of diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Publication of medical texts; Publication of medical texts in the field of diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Publishing of scientific papers in relation to medical technology; Publishing of scientific papers in relation to medical technology in the field of diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Publishing and issuing scientific papers in relation to medical technology; Publishing and issuing scientific papers in relation to medical technology in the field of diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Education, entertainment and sport services; Education, entertainment and sport services in relation to diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Education and instruction services; Education and instruction services in relation to diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Provision of information on diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders via an online portal; Specialisation courses for doctors; Specialisation courses for doctors in the field of diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Personnel training; Personnel training in the field of diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Educational services provided by medical assistants; Educational services provided by medical assistants in the field of diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders. Science and technology services; Science and technology services in the field of diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Issuing of scientific information; Issuing of scientific information in the field of diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Provision of scientific information; Provision of scientific information in the field of diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Natural science services; Natural science services in the field of diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Providing science technology information; Providing science technology information in the field of diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Compilation of scientific information; Compilation of scientific information in the field of diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; IT services; IT services for data protection; Hosting of databases; Hosting of databases in relation to diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Medical and pharmacological research services; Medical and pharmacological research services in the field of diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Information technology services for the pharmaceutical and healthcare industries; Information technology services for the pharmaceutical and healthcare industries in the field of diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Providing information on clinical studies via an interactive website; Providing information on clinical studies via an interactive website in the field of diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Providing information about the results of clinical trials for pharmaceutical products; Providing information about the results of clinical trials for pharmaceutical products in relation to diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Providing scientific information in the field of medical disorders, their treatment, prevention and screening; Providing scientific information in the field of diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders, their treatment, prevention and screening; Provision of information and data relating to medical and veterinary research and development; Provision of information and data relating to medical and veterinary research and development in the field of diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials in the field of diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Genetic research; Genetic research in the field of diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Genetic mapping for scientific purposes; Genetic mapping for scientific purposes in the field of diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Scientific research in the field of diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Research and development services in the field of immunology; Research and development services in the field of immunology in relation to diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Hosting web portals; Hosting web portals in relation to diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Hosting of portals on the internet; Hosting of portals on the internet in relation to diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders. Human healthcare services; Human healthcare services in relation to diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Medical services; Medical services in relation to diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Providing information via the Internet in the field of diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Providing medical information; Providing medical information in the field of diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Providing health information; Providing health information in the field of diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Providing on-line information relating to the prevention, treatment and screening of diabetes, autoimmune diabetes, autoimmune diseases and metabolic disorders; Diabetes, autoimmune diabetes, autoimmune diseases and metabolic disorders screening services; Genetic counseling in the field of diabetes, autoimmune diabetes, autoimmune diseases and metabolic disorders; Genetic testing for medical purposes; Genetic testing for medical purposes in the field of diabetes, autoimmune diabetes, autoimmune diseases and metabolic disorders; Genetic testing for diagnostic or treatment purposes; Genetic testing for diagnostic or treatment purposes in the field of diabetes, autoimmune diabetes, autoimmune diseases and metabolic disorders; Medical and health services relating to DNA, genetics and genetic testing; Medical and health services relating to DNA, genetics and genetic testing in the field of diabetes, autoimmune diabetes, autoimmune diseases and metabolic disorders; Medical services in the field of diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Immunodetection services for medical purposes; Immunodetection services for medical purposes in the field of diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Advice relating to immunology; Advice relating to immunology in relation to diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Performing diagnosis of diseases; Performing diagnosis of diabetes, autoimmune diabetes, autoimmune diseases and metabolic disorders; Medical screening services relating to diabetes, autoimmune diabetes, genetics, autoimmune diseases and metabolic disorders; Conducting screenings for diabetes, autoimmune diabetes, autoimmune diseases and metabolic disorders risk factors; Genetic counseling; Genetic counseling in relation to diabetes, autoimmune diabetes, autoimmune diseases and metabolic disorders; Medical testing; Medical testing in relation to diabetes, autoimmune diabetes, autoimmune diseases and metabolic disorders; Medical testing for diagnostic or treatment purposes; Medical testing for diagnostic or treatment purposes in relation to diabetes, autoimmune diabetes, autoimmune diseases and metabolic disorders; Collection and preservation of human blood; Collection and preservation of human blood in relation to diabetes, autoimmune diabetes, autoimmune diseases and metabolic disorders; Medical services relating to the removal, treatment and processing of umbilical cord blood; Medical services relating to the removal, treatment and processing of umbilical cord blood in relation to diabetes, autoimmune diabetes, autoimmune diseases and metabolic disorders; Medical services relating to the removal, treatment and processing of human blood; Medical services relating to the removal, treatment and processing of human blood in relation to diabetes, autoimmune diabetes, autoimmune diseases and metabolic disorders; Medical laboratory services for the analysis of blood samples taken from patients; Medical laboratory services for the analysis of blood samples taken from patients in relation to diabetes, autoimmune diabetes, autoimmune diseases and metabolic disorders; Blood banks; Blood bank services; Cord blood bank services; Hospital services; Clinics; Clinics (Medical -); Medical treatment and diagnostics services provided by clinics and hospitals; Medical assistance consultancy provided by doctors and other specialized medical personnel.

Abstract

The present invention relates to a kit-of-parts comprising at least one mitochondrial uncoupler and at least one cationic amphiphilic drug and its use in medicine. The invention further relates to a pharmaceutical composition comprising at least one mitochondrial uncoupler and at least one cationic amphiphilic drug for use in medicine. Moreover, the invention is directed to the kit-of-parts and the pharmaceutical composition for use in the treatment of cancer, in particular glioma, pancreatic cancer, small cell lung cancer, metastatic prostate cancer, liver cancer and triple-negative breast cancer.

IPC Classes  ?

• A61K 31/609 - Amides, e.g. salicylamide
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil

Abstract

The present invention provides a pharmaceutical composition comprising an antibody, which binds to human SRRM2 present on the cell surface of a target cell and optionally a pharmaceutically acceptable carrier, diluent or excipient. The present invention further provides said pharmaceutical composition for use in a method for the treatment of cancer in a human subject. Further is provided a method for determining whether a human subject may suffer from cancer, comprising determining in a sample obtained from said human subject whether SRRM2 is present on the cell surface of cells comprised by said sample. Additionally, an antibody, which binds to human SRRM2 present on the cell surface of a target cell is provided and an antibody, which binds to human SRRM2 present on the cell surface of a target cell for use in a method of killing said target cell having human SRRM2 present on the cell surface.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61P 35/00 - Antineoplastic agents
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/725 - T-cell receptors

Abstract

The present invention generally relates to the use of metabolic biomarkers for the diagnosis of endometriosis, and more specifically to an ex vivo method for diagnosing endometriosis in a subject. The present invention further relates to a system and kit for diagnosing endometriosis.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/92 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving lipids, e.g. cholesterol

Abstract

The present invention provides herpesviruses, such as EBV, which lack at least one viral miRNA. Such herpesviruses lacking at least one viral miRNA are advantageously not capable of packaging their genome into the capsid, thereby producing HVLPs, which are substantially free of their herpesvirus genome or the nucleic acid molecule encoding the proteinaceous part of the HVLP and viral miRNA. Such HVLPs may be used as vaccine.

IPC Classes  ?

• A61K 39/245 - Herpetoviridae, e.g. herpes simplex virus
• A61P 31/22 - Antivirals for DNA viruses for herpes viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The invention provides a method for determining whether or not virus-neutralizing antibodies are present in a sample obtained from a subject and a respective kit therefore. The present invention further relates to an in vitro method for screening compounds for their ability to neutralize a virus.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present invention relates to a genetically controlled nanoscopy contrast-generating unit comprising a metal interactor, wherein the metal interactor is compatible with nanoscopy fixation protocols, nanoscopy post-fixation protocols, and nanoscopy metal staining protocols and wherein the metal interactor is a molecule to which metal ions can bind to or react with. The present invention also relates to a genetically controlled structural element, wherein said genetically controlled structural element organizes the genetically controlled nanoscopy contrast-generating unit. The genetically controlled structural element can be an encapsulin and the genetically controlled nanoscopy contrast-generating unit can be one or two murine metallothionein-3, or three chimeric metallothioneins. The present invention also relates to a genetically controlled scaffold, wherein said genetically controlled scaffold spatially organizes the genetically controlled structural elements. The present invention also relates to the use of such genetically controlled nanoscopy contrast-generating unit, such genetically controlled structural element, and/or such genetically controlled scaffold for nanoscopy detection methods. The present invention also relates to a nanobiomaterial consisting of the isolated genetically controlled structural elements, and/or genetically controlled scaffolds. The present invention also relates to vectors comprising a nucleic acid encoding a genetically controlled nanoscopy contrast-generating unit, a genetically controlled structural element, and/or a genetically controlled scaffold.

IPC Classes  ?

• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• C07K 14/825 - Metallothioneins
• G01N 1/30 - StainingImpregnating
• G01N 33/84 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving inorganic compounds or pH
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites

Abstract

The present invention relates to a method for detecting a nucleic acid construct or part thereof and/or for detecting the expression product of the nucleic acid construct or part thereof, wherein the method comprises inserting a nucleic acid construct or part thereof into an intron or a synthetic intron, wherein the nucleic acid construct comprises certain defined structures according to the present invention. The present invention also relates to the various uses of the method described herein, to the nucleic acid construct, a vector comprising said nucleic acid construct, a cell comprising said nucleic acid construct and/or said vector, and a respective kit.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

The present invention relates to methods of producing axial stem cells (AxSCs) as well to axial stem cells (AxSCs) produced by such methods and uses thereof. The present invention further relates to axial stem cells (AxSCs), wherein said axial stem cells are not pluripotent cells, but are, for example, region-specific multipotent stem cells capable of indefinitely renewing themselves.

IPC Classes  ?

• C12N 5/0797 - Stem cellsProgenitor cells
• A61K 35/30 - NervesBrainEyesCorneal cellsCerebrospinal fluidNeuronal stem cellsNeuronal precursor cellsGlial cellsOligodendrocytesSchwann cellsAstrogliaAstrocytesChoroid plexusSpinal cord tissue

Abstract

The present invention relates to novel anti-FLT3 antibodies for specifically targeting extracellular domain of FLT3. The present invention further relates to targeting FLT3 by novel antibody-drug- conjugates (ADCs) based on the novel anti-FLT3 antibodies of the present invention, especially in combination with kinase inhibitors, for use in therapy and/or for use in a method of cancer treatment (e.g., acute myeloid leukemia (AML) with or without internal tandem duplication (ITD) mutations in the FLT3 gene (FLT3-ITD)).

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention relates to the field of (bio-)medicine, and more particularly to the treatment of copper-related diseases. Novel means and methods for depleting (excess) copper from organs and/or the circulation are provided. Agents with a high copper binding affinity and stabilized forms thereof are provided, as well as a novel treatment regimen. The means and methods of the present invention are particularly useful for treatment of Wilson Disease, but also for treatment of other conditions.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present invention relates to a compound for use in a method for the modulation of movement of extracellular matrix (ECM) produced by mesothelial cells forming the surface of an internal organ, towards a site of injury of said organ of a subject suffering from or being at a risk of an injury of said organ. Additionally, the present invention relates to a compound for use in a particular in vivo screening method for identifying a modulator of movement of extracellular matrix (ECM) produced by mesothelial cells towards a site of injury of an internal organ of a subject. Further, the present invention relates to a specific in vitro screening method for identifying a modulator of the movement of ECM towards an external stimulus in a single cell suspension derived from the mesothelium.

IPC Classes  ?

• C07K 14/495 - Transforming growth factor [TGF]
• C12N 15/86 - Viral vectors

Abstract

Methods and systems are described for fabricating thin hydrogel layers on biosensors by a drop-spin method, which includes placing a drop of the hydrogel on the electrode, spinning the wafer at high speed in a vacuum, and heating the wafer to cure. One and multilayer sensors can be fabricated in this way, by adding layers of hydrogel or metal.

IPC Classes  ?

• G01N 27/327 - Biochemical electrodes

Abstract

The invention provides a method of preparing a biocompatible hydrogel, a hydrogel obtainable by said method, a biocompatible hydrogel for non-covalent immobilization of one or more enzyme(s), and a composition comprising any of said hydrogels. The invention further provides a method for encapsulating one or more enzyme(s) in a hydrogel as described herein and the use of any of said hydrogels for non-covalent immobilization of one or more enzyme(s) in the hydrogel or the use of any of said hydrogels in a biosensor. Additionally, the present invention provides a kit comprising the composition or the hydrogel according to the present invention.

IPC Classes  ?

• C08L 5/08 - ChitinChondroitin sulfateHyaluronic acidDerivatives thereof
• C08B 37/08 - ChitinChondroitin sulfateHyaluronic acidDerivatives thereof
• C08L 5/00 - Compositions of polysaccharides or of their derivatives not provided for in group or
• C08L 5/02 - DextranDerivatives thereof
• C08L 5/04 - Alginic acidDerivatives thereof
• C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
• C08B 37/02 - DextranDerivatives thereof

Abstract

Methods and systems are described for fabricating thin hydrogel layers on biosensors by a drop-spin method, which includes placing a drop of the hydrogel on the electrode, spinning the wafer at high speed in a vacuum, and heating the wafer to cure. One and multilayer sensors can be fabricated in this way, by adding layers of hydrogel or metal.

IPC Classes  ?

• G01N 27/327 - Biochemical electrodes

Abstract

The present invention refers to novel UV-light cleavable drug conjugates comprising a diazirine linker.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
• C07D 203/04 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
• A61K 38/26 - Glucagons

Abstract

in vitroin vitro method. Additionally, the present invention relates to a culture medium and the respective use of said culture medium in any of said methods according to the present invention.

IPC Classes  ?

• C12N 5/09 - Tumour cells
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

The present invention relates to an ex vivo analytic method for analysis of a sample (S1), comprising the steps: A) Determining Fe2+, Fe3+, Fe-Ferritin and total Fe content in sample (S1), comprising the steps: A1) Separating simultaneously Fe2+, Fe3+and Fe-Ferritin present in a sample (S1); and A2) Quantifying simultaneously Fe2+, Fe3+, Fe-Ferritin separated in step A1) and total Fe based on sample (S1); B) Determining S and Se containing compounds content of sample (S1), comprising the steps B1) Separating simultaneously S and Se containing compounds present in sample (S1); and B2) Quantifying simultaneously S and Se containing compounds separated in step B1) of sample (S1). Further, the invention relates to a kit for performing the analytic method.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 27/447 - Systems using electrophoresis
• G01N 33/84 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving inorganic compounds or pH

Abstract

The present invention relates to a composition comprising proteins identified in barn dust extract or peptides derived from one of the proteins. The composition is useful in the prevention or treatment of a disease.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 38/38 - Albumins
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 37/08 - Antiallergic agents

Abstract

The present invention provides a novel IGFR-like receptor and antagonists and agonists for targeting said receptor. Said antagonists and agonists are envisaged for use as a medicament, and in particular for treatment of diabetes.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• C07K 16/06 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies from serum

Abstract

The present invention relates a vector system and a vector system for use in a method of treating a disease, each comprising a first vector and a second vector. The present invention further relates to the first vector, the second vector and a combination of the first vector and the second vector. In addition, the present invention relates to a pharmaceutical composition comprising the vector system of the invention or the combination of the invention.

IPC Classes  ?

• C12N 15/861 - Adenoviral vectors
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

The invention relates to a device and a method for determining one or more parameters regarding a content and/or property of biomolecules, in particular metabolites, in a biological tissue (11). The device comprises at least one irradiation unit (1) configured to irradiate the tissue (11) with electromagnetic radiation (2) exhibiting one or more wavelengths or wavelength ranges, in particular in the mid-infrared, near-infrared and/or visible spectral range, at least one detection unit (8, 12) configured to detect, in a spatially resolved manner, first signals corresponding to optical and/or optoacoustic and/or optothermal signals emanating from the tissue (11) in response to irradiating the tissue (11) with electromagnetic radiation (2), in particular in the near-infrared and/or visible spectral range, wherein the at least one irradiation unit (1) and the at least one detection unit (8, 12) are located in the same half space above and/or adjacent to the irradiated tissue (11), and a processing unit (14) configured i) to localize, based on the detected first signals, a location or region of interest on and/or within the tissue (11), at which at least one biomolecule of interest is present or expected, ii) to control the at least one irradiation unit (1) to irradiate the location or region of interest on and/or within the tissue (11) with electromagnetic radiation (2) exhibiting a time-varying intensity and one or more wavelengths or wavelength ranges in the mid-infrared spectral range, iii) to control the at least one detection unit (8, 12) to detect second signals corresponding to optoacoustic and/or optothermal signals emanating from the irradiated location or region of interest on and/or within the tissue (11) in response to irradiating the location or region of interest on and/or within the tissue (11) with the electromagnetic radiation (2) in the mid-infrared spectral range, and iv) to determine, based on the detected second signals, one or more parameters regarding a content and/or property of the at least one biomolecule, in particular metabolite, of interest at the location or region of interest on and/or within in the tissue (11).

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
• G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated
• G01N 29/036 - Analysing fluids by measuring frequency or resonance of acoustic waves
• G01N 29/06 - Visualisation of the interior, e.g. acoustic microscopy

Abstract

The present invention provides novel IGFR-L1 antibodies for targeting extracellular domain of non-denatured IGFR-L1 protein. Said antibodies are envisaged for use as a medicament, and in particular for treatment of diabetes and related disorders and cancer.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention relates to a novel dimer composed of a first Fab monomer and a second Fab monomer, each Fab monomer comprising a VH and a VL region, wherein two of such VH or VL regions are covalently linked by a disulfide bond between an additional non- naturally occurring cysteine residue at their respective N-termini.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to new cinnamic add amides which may be used for treatment of fibrosis and neoplasia and to cinnamic acid amides for use in the treatment of fibrosis, neoplasia, arthrolithiasis, familiar mediterranean fever and pericarditis. Further, the invention relates to a pharmaceutical composition comprising said cinnamic acid amides and to a screening essay for identifying compounds suitable for the treatment of fibrosis.

IPC Classes  ?

• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/42 - Oxazoles
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 17/00 - Drugs for dermatological disorders
• A61P 35/00 - Antineoplastic agents
• C07C 233/00 - Carboxylic acid amides
• C07D 213/00 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
• C07D 249/00 - Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
• C07D 311/00 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
• C07D 319/00 - Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
• A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
• A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
• A61K 31/4192 - 1,2,3-Triazoles
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• C07C 235/38 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
• C07D 213/643 - 2-PhenoxypyridinesDerivatives thereof
• C07D 213/75 - Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
• C07D 231/20 - One oxygen atom attached in position 3 or 5
• C07D 307/81 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
• C07D 311/14 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 6 and unsubstituted in position 7
• C07D 317/60 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Goods & Services

Information (Education -); Publishing, reporting, and writing of texts; Publishing of medical publications; Publication of medical texts; Publishing of scientific papers in relation to medical technology; Publishing and issuing scientific papers in relation to medical technology; Education, entertainment and sport services; Education and instruction services; Provision of information on fitness training via an online portal; Arranging and conducting of in-person educational forums; Dietary education services; Instruction in diet [not medical]; Conducting training courses relating to diet online; Provision of educational courses relating to diet; Training related to nutrition; Conducting classes in nutrition; Instruction in nutrition [not medical]; Conducting training courses relating to nutrition online. Science and technology services; Issuing of scientific information; Provision of scientific information; Natural science services; Issuing of toxicological information; Providing science technology information; Compilation of scientific information; IT services; Medical and pharmacological research services; Information technology services for the pharmaceutical and healthcare industries; Providing information on clinical studies via an interactive website; Providing information about the results of clinical trials for pharmaceutical products; Providing scientific information in the field of medical disorders and their treatment; Provision of information and data relating to medical and veterinary research and development; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Technical consultancy in relation to research services relating to foods and dietary supplements. Human healthcare services; Medical services; Providing information via the Internet in the field of diabetes; Providing medical information; Providing health information; Dietetic advisory services; Dietary guidance; Dietary advice; Dietary and nutritional advice; Weight reduction diet planning and supervision; Providing on-line information relating to the prevention of cardiovascular disease, strokes, metabolic syndrome and obesity; Providing on-line information relating to the prevention and therapy of non-communicable diseases (NCDs), particularly heart diseases, strokes, cancers, diabetes, chronic lung diseases, Parkinson's disease, autoimmune diseases, chronic kidney diseases, osteoarthritis, osteoporosis, Alzheimer's disease and cataracts; Providing information about dietary supplements and nutrition; Providing information relating to dietary and nutritional supplements; Nutrition consultancy.

Abstract

The present invention relates to a cell of the human immune system transduced or transfected with a T cell receptor (TCR) or chimeric antigen receptor (CAR), said cell being further modified to render its MALT1 protease activity constitutive active. The present invention further relates a said cell of the human immune system for use as a medicament. In particular, the present invention relates to said cell for use in adoptive T cell therapy. The invention also comprises a cell of the human immune system transduced or transfected with a T cell receptor (TCR) or chimeric antigen receptor (CAR), and further modified to render its MALT1 protease activity constitutive active for use in a method of treating cancer. The invention also relates to a method for generating a cell of the human immune system, comprising modifying a cell to render MALT1 protease activity constitutive active. The invention further relates to an in vitro method of enhancing the activity of a cell of the human immune system transduced or transfected with a T cell receptor (TCR) or chimeric antigen receptor (CAR), comprising modifying said cell in that MALT1 is rendered constitutive active. The invention also comprises an in vitro use of constitutive active MALT1 for enhancing the activity of a cell transduced or transfected with a T cell receptor (TCR) or chimeric antigen receptor (CAR).

IPC Classes  ?

• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention provides for methods for identifying modulators of extracellular matrix (ECM) movement towards a site requiring deposition of ECM. Such modulators can be applied for use in a method for the modulation of ECM movement towards a site requiring deposition of ECM, e.g. a wound, thereby allowing treatment of a condition involving ECM deposition. Since the modulator may either be an inhibitor or promoter, either excessive or insufficient ECM deposition could be dealt with by the means and methods of the present invention.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The present invention relates to a method for preparing a bactericidal phage vector, (pharmaceutical) compositions comprising such phage vectors, also for use in treating diseases, particularly those caused by (antimicrobial resistance) bacterial cells.

IPC Classes  ?

• C12N 15/64 - General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

Abstract

The invention relates to a method, an apparatus and system for characterizing transient interactions between biomolecules, wherein the method comprises following steps: providing a plurality of plasmonic nanoparticles which are configured to allow first biomolecules to adhere thereto; providing a mixture comprising the nanoparticles, first biomolecules and second biomolecules to allow the first biomolecules to adhere to the nanoparticles and to allow the second biomolecules to, in particular transiently, interact with the first biomolecules adherent to the nanoparticles; irradiating the mixture with first electromagnetic radiation, in particular broadband electromagnetic radiation; detecting second electromagnetic radiation, which is scattered by the mixture while irradiating the mixture with the first electromagnetic radiation, in a time-resolved and spectrally-resolved manner so as to obtain intensity signals representing changes in the spectrum of the detected second electromagnetic radiation; and determining at least one interaction parameter characterizing transient interactions of the second biomolecules with the first biomolecules based on the intensity signals.

IPC Classes  ?

• G01N 21/552 - Attenuated total reflection
• G01N 21/27 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection

Abstract

The present invention relates to CRISPR-mediated means and methods, e.g., for adjustably induction of multiple gene expression and subsequent cell reprogramming. Particularly, the CRISPR-mediated means and methods of the present invention relate to conversion of endogenous glial cells into GABAergic neurons representing an effective method for cell reprogramming.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

Described herein is a genetically modified plant or non-human animal having reduced expression of an endogenous target gene.

IPC Classes  ?

• A01K 67/027 - New or modified breeds of vertebrates
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

The present invention relates to a methanobactin reducing Fe3+ ions to Fe2+ ions for use in medicine and a pharmaceutical composition comprising said methanobactin as well as to a process for reducing Fe3+ ions to Fe2+ ions ex vivo.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 3/00 - Drugs for disorders of the metabolism
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid

Abstract

The present invention relates to systems, methods and fluorescent polypeptide for real-time multicolor shortwave infrared fluorescence imaging. The systems and methods of the present invention further relate to real-time multi-color in vivo SWIR imaging systems employing high-power excitation sources in combination with state of the art InGaAs SWIR detectors and SWIR illuminated fluorescent polypeptide.

IPC Classes  ?

• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G01N 21/64 - FluorescencePhosphorescence

Abstract

The present invention relates to systems, methods and fluorophores for real-time multicolor shortwave infrared fluorescence imaging. The systems and methods of the present invention further relate to real-time multi-color in vivo SWIR imaging systems employing high-power excitation sources in combination with state of the art InGaAs SWIR detectors and SWIR illuminated fluorophores.

IPC Classes  ?

• G01N 21/64 - FluorescencePhosphorescence

Abstract

The present invention relates to a fusion protein (FcsFNDC4) comprising a) a soluble FNDC4 (sFNDC4) or a functional fragment thereof; b) a peptide linker; and c) a Fc-domain. The present invention further relates to a nucleic acid molecule comprising a nucleotide sequence encoding said fusion protein, a vector comprising said nucleic acid molecule, and a host cell comprising the vector or the nucleic add molecule. The present invention also relates to a fusion protein for use in therapy. In particular, the present invention relates to a fusion protein for use in a method of preventing and/or treating diabetes or inflammation in a subject. The invention also relates to a composition comprising at least one fusion protein. Further, the present invention relates to a kit comprising said fusion protein or said composition. The invention also comprises a method of producing the fusion protein and a method of stratifying a subject with diabetes applying the fusion protein of the invention.

IPC Classes  ?

• C12N 15/62 - DNA sequences coding for fusion proteins
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The present invention relates to composition comprising a clustered, regularly interspaced, short palindromic repeats (CRISPR) system comprising i) at least one CRISPR-associated protein 13 (Cas13) or a nucleotide sequence encoding said Cas13 protein fused with at least one nuclear localization signal (NLS) fused to at least one nuclear export sequence (NES) and ii) at least one guide RNA (gRNA) or a nucleotide sequence encoding said gRNA capable of hybridizing with one or more target RNA molecules. Further, the invention relates to a composition comprising a clustered, regularly interspaced, short palindromic repeats (CRISPR) system comprising i) at least one CRISPR-associated protein 13 (Cas13) or a nucleotide sequence encoding said Cas13 protein fused with at least one nuclear localization signal (NLS) or with at least one nuclear export sequence (NES) and ii) at least one guide RNA (gRNA) or a nucleotide sequence encoding said gRNA capable of hybridizing with one or more target RNA molecules, which is fused to at least one viral export element. The present invention also relates to said compositions for use in therapy. In particular, the present invention relates to said compositions for use in a method of preventing or treating a viral or a bacterial disease in a subject. The present invention further relates to nucleic acid molecules comprising a nucleotide sequence encoding said Cas13 protein and/or said gRNA of said compositions, vectors comprising said nucleic acid molecules and host cells comprising the vectors or the nucleic acid molecules. Further, the present invention relates to kits comprising the compositions. The invention also comprises methods of producing said compositions of the present invention.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 9/22 - Ribonucleases

Abstract

The present invention relates to a composition, comprising at least one compound according to formula (I) as well as to a composition comprising at least one compound according to formula (I) and/or dimers of compounds according to formula (I) in particular for use in the treatment of diseases caused by betacoronaviruses, leishmaniasis, and trypanosomiasis.

IPC Classes  ?

• A61K 31/473 - QuinolinesIsoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
• A61P 31/14 - Antivirals for RNA viruses
• C07D 401/02 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings

Abstract

The present invention provides a pharmaceutical composition comprising an antibody which binds to human PRDX4 present on the cell surface of a target cell and optionally a pharmaceutically acceptable carrier, diluent or excipient. The present invention further provides said pharmaceutical composition for use in a method for the treatment of cancer in a human subject. Further is provided a method for determining whether a human subject may suffer from cancer, comprising determining in a sample obtained from said human subject whether PRDX4 is present on the cell surface of cells comprised by said sample. Additionally, an antibody which binds to human PRDX4 present on the cell surface of a target cell is provided.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/725 - T-cell receptors
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

In various embodiments a biocompatible composite membrane for in vitro cell culturing comprising a first material, which is non-water soluble and a water soluble second material is provided, wherein the composite membrane comprises a porous scaffold and a filling layer, the scaffold comprising the first material and the filling layer comprising the second material. Further, a method for fabricating the membrane, a bioreactor for use of the membrane in cell-stretch experiments and a corresponding method for investigating cells attached to the biocompatible composite membrane are also provided.

IPC Classes  ?

• C12M 3/04 - Tissue, human, animal or plant cell, or virus culture apparatus with means providing thin layers
• A61L 26/00 - Chemical aspects of, or use of materials for, liquid bandages
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12M 1/42 - Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic wave
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters

Abstract

An apparatus for photo-acoustic measurement of a measurement target in a fluid flow comprises: - an ellipsoidal measurement chamber (3) having a first focal point and a second focal point; - a duct (6, 7, 8) configured to guide a fluid flow through the measurement chamber (3) along a first axis (X) through the first focal point; - light source means for generating an excitation light beam of modulated intensity; - means configured to pass the excitation light beam through the measurement chamber (3) along a second axis (Y), which is different from the first axis (X), such that the excitation light beam crosses the fluid flow at the first focal point and that the crossing of the fluid flow and the excitation light beam defines an excitation volume (4) within which the fluid flow is excited by the excitation light beam to generate acoustic waves; and - detecting means (5) arranged at the second focal point and configured to detect said acoustic waves, wherein the detecting means has no direct contact with the fluid flow, and wherein the ellipsoidal measurement chamber has inner walls that are configured to focus the acoustic waves generated by the excitation light beam within the excitation volume (4) onto the detecting means (5).

IPC Classes  ?

• G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated
• G01N 21/47 - Scattering, i.e. diffuse reflection

Abstract

The present invention relates to a compound for use in a method of reducing the formation of heliocytes causing adhesiogenesis. An in vitro assay for the formation of heliocyte and/or the formation of adhesions is also comprised herein, as well as methods comprising the use of said in vitro assay. It also relates to a pharmaceutical composition for use in a method of reducing the formation of heliocytes comprising the compound mentioned above.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
• A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
• A61K 31/4422 - 1,4-Dihydropyridines, e.g. nifedipine, nicardipine
• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim

Abstract

The invention provides a method for manufacturing a HEK293 cell line, which is capable of producing Epstein-Barr virus-like particles (EB-VLPs), as well as the HEK293 cell line obtainable by said method. The invention is further directed to a method for manufacturing EB-VLPs and a composition comprising EB-VLPs obtainable by said method for manufacturing EB-VLPs. Additionally, the invention provides a kit comprising EB-VLPs generated according to the method for manufacturing EB-VLPs. Further, the invention relates to a method for manufacturing a vaccine as well as the vaccine containing EB-VLPs obtainable by said method for manufacturing EB-VLPs.

IPC Classes  ?

• A61K 39/245 - Herpetoviridae, e.g. herpes simplex virus
• C12N 7/04 - Inactivation or attenuationProducing viral sub-units
• C12N 15/869 - Herpesviral vectors

Abstract

The invention provides a method for determining whether or not virus-neutralizing antibodies are present in a sample obtained from a subject and a respective kit therefore. The present invention further relates to an in vitro method for screening compounds for their ability to neutralize a virus.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The invention provides a method for determining whether or not virus-neutralizing antibodies are present in a sample obtained from a subject and a respective kit therefore. The present invention further relates to an in vitro method for screening compounds for their ability to neutralize a virus.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role. The compounds and pharmaceutical compositions described herein are also useful in the treatment of a condition, disorder or disease that is characterised by oxidative stress or where oxidative stress is likely to play or plays a substantial role; and/or a condition, disorder or disease that is characterised by activation of (1) one or more components of the necrosome; (2) death domain receptors; and/or (3) Toll-like receptors; and/or (4) players in ferroptotic/ferroptosis signalling, or where activation of any one of (1) to (3) and/or (4) is likely to play or plays a substantial role.

IPC Classes  ?

• C07D 495/10 - Spiro-condensed systems
• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61K 31/499 - Spiro-condensed pyrazines or piperazines
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• C07D 241/36 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
• C07D 241/42 - Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 471/10 - Spiro-condensed systems
• C07D 487/10 - Spiro-condensed systems
• C07D 491/06 - Peri-condensed systems
• C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Abstract

The present invention relates to a kit-of-parts comprising at least one mitochondrial uncoupler and at least one cationic amphiphilic drug and its use in medicine. The invention further relates to a pharmaceutical composition comprising at least one mitochondrial uncoupler and at least one cationic amphiphilic drug for use in medicine. Moreover, the invention is directed to the kit-of-parts and the pharmaceutical composition for use in the treatment of cancer, in particular glioma, pancreatic cancer, small cell lung cancer, metastatic prostate cancer, liver cancer and triple-negative breast cancer.

IPC Classes  ?

• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/609 - Amides, e.g. salicylamide
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention provides a novel IGFR-like receptor 2 and antagonists and agonists for targeting said receptor. Said antagonists and agonists are envisaged for use as a medicament, and in particular for treatment of cancer or diabetes.

IPC Classes  ?

• C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates an in-vitro method for diagnosis and/or prognosis of a disease in a tissue sample obtained from a mammalian subject comprising (i) Determining the level of a first biomarker using matrix-assisted laser desorption/ionization (MALDI)-imaging in the sample; (ii) Performing a histochemical staining of the sample; (iii) Determining the ratio of the levels of a second biomarker and a reference marker using fluorescence in situ-hybridization (FISH); wherein the same sample is used in steps (i) to (iii).

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6841 - In situ hybridisation
• G01N 1/30 - StainingImpregnating

Abstract

The present invention relates to a method of preparing a barn dust extract, said barn dust extract, and a composition comprising said barn dust extract. The barn dust extract is useful in the prevention or treatment of a disease.

IPC Classes  ?

• A61K 35/02 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
• A61P 37/08 - Antiallergic agents

Abstract

The present invention relates to a method for detecting a nucleic acid construct or part thereof and/ or for detecting the expression product of the nucleic acid construct or part thereof, wherein the method comprises inserting a nucleic acid construct or part thereof into an intron or a synthetic intron, wherein the nucleic acid construct comprises certain defined structures according to the present invention. The present invention also relates to the various uses of the method described herein, to the nucleic acid construct, a vector comprising said nucleic acid construct, a cell comprising said nucleic acid construct and/ or said vector, and a respective kit.

IPC Classes  ?

• C12N 15/79 - Vectors or expression systems specially adapted for eukaryotic hosts

Abstract

The present invention relates to a nucleic acid molecule encoding (I) a polypeptide having the activity of an endonuclease, which is (a) a nucleic acid molecule encoding a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1; (b) a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO: 2; (c) a nucleic acid molecule encoding an endonuclease, the amino acid sequence of which is at least 70% identical to the amino acid sequence of SEQ ID NO: 1; (d) a nucleic acid molecule comprising or consisting of a nucleotide sequence which is at least 50% identical to the nucleotide sequence of SEQ ID NO: 2; (e) a nucleic acid molecule which is degenerate with respect to the nucleic acid molecule of (d); or (f) a nucleic acid molecule corresponding to the nucleic acid molecule of any one of (a) to (e) wherein T is replaced by U; (II) a fragment of the polypeptide of (I) having the activity of an endonuclease. Also, the present invention relates to a vector comprising the nucleic acid molecule and a protein encoded by said nucleic acid molecule. Further, the invention relates to a method of modifying the genome of a eukaryotic cell and a method of producing a non-human vertebrate or mammal.

IPC Classes  ?

• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• A01K 67/027 - New or modified breeds of vertebrates
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12N 9/22 - Ribonucleases
• C12N 5/075 - OocytesOogonia
• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria

Abstract

The invention relates to an otoscope (100), comprising a light source (108) configured to emit light to illuminate an ear canal, visualization means (106) configured to display the ear canal illuminated by the light emitted by the light source (108) for visual inspection of the ear canal by a user, a spectral sensor (110) configured to measure intensities of the light emitted by the light source (108) and reflected by the ear canal, the spectral sensor (110) being configured to measure at least a first intensity in a first spectral range and a second intensity in a second spectral range, and a controller (112) configured to calculate a parameter on the basis of the first intensity and the second intensity.

IPC Classes  ?

• A61B 1/227 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for ears, i.e. otoscopes
• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• A61B 1/06 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with illuminating arrangements
• A61B 1/07 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with illuminating arrangements using light-conductive means, e.g. optical fibres

Abstract

The invention provides a method for detecting a specific splice event of a gene of interest, wherein the specific splice event creates a specific splice product, which comprises an exon of interest, wherein the method comprises: (i) Inserting a split intein—heterologous polynucleotide construct into the exon of interest, wherein the split intein comprises an N-terminal splicing region upstream of the heterologous polynucleotide and a C-terminal splicing region downstream of the heterologous polynucleotide; and (ii) detecting the heterologous polynucleotide and/or the expression product of the heterologous polynucleotide. The present invention also provides the use of the split intein—heterologous polynucleotide construct, the nucleic acid encoding this construct, the vector and the host cell comprising the nucleic acid as well as a kit for detecting a specific splice event of a gene of interest.

IPC Classes  ?

• C12N 15/65 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression using markers
• C12N 9/50 - Proteinases
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof

Abstract

The present invention relates to methods of producing axial stem cells (AxSCs) as well to axial stem cells (AxSCs) produced by such methods and uses thereof. The present invention further relates to axial stem cells (AxSCs), wherein said axial stem cells are not pluripotent cells, but are, for example, region-specific multipotent stem cells capable of indefinitely renewing themselves.

IPC Classes  ?

• C12N 5/0793 - Neurons
• C12N 5/0797 - Stem cellsProgenitor cells

Abstract

The present invention relates to a bradykinin B2 receptor (BKB2R)-antagonist for use in a method of preventing progression of SARS-CoV2-infection in a patient, or for use in a method of treating a SARS-CoV2-infection in a patient. Furthermore, the present invention relates to pharmaceutical compositions comprising a BKB2R-antagonist and to their uses.

IPC Classes  ?

• A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof
• A61P 31/14 - Antivirals for RNA viruses